Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.Flavia Salvi, Alessandro Levis, Daniela Gioia et al.|Blood|2005Cited by 4
P104 Prognostic role of transfusion requirement in myelodysplastic syndromesFlavia Salvi, Alessandro Levis, Monia Lunghi et al.|Leukemia Research|2007Cited by 1
P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS RegisterDaniela Gioia, A. Levis, Daniela Cilloni et al.|Leukemia Research|2007Cited by 0
Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndrome.Flavia Salvi, Alessandro Levis, Daniela Gioia et al.|Blood|2009Cited by 0
A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients.Dario Ferrero, Mario Boccadoro, Chiara Maria Dellacasa et al.|Blood|2005Cited by 0